A citation-based method for searching scientific literature

Fernando Barata, Carlos Aguiar, Tiago Reis Marques, José Bravo Marques, Venceslau Hespanhol. Drug Saf 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
209
100

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
100

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Todd M Bauer, Alice T Shaw, Melissa L Johnson, Alejandro Navarro, Justin F Gainor, Holger Thurm, Yazdi K Pithavala, Antonello Abbattista, Gerson Peltz, Enriqueta Felip. Target Oncol 2020
37
100

Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
Loay Kassem, Kyrillus S Shohdy, Shaimaa Lasheen, Omar Abdel-Rahman, Ahmad Ali, Raafat R Abdel-Malek. Crit Rev Oncol Hematol 2019
22
100

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.
Emanuel Raschi, Milo Gatti, Francesco Gelsomino, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti. Target Oncol 2020
43
100



Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Danilo Rocco, Ciro Battiloro, Luigi Della Gravara, Cesare Gridelli. Drug Saf 2019
7
100

Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Takeshi Hirota, Shota Muraki, Ichiro Ieiri. Clin Pharmacokinet 2019
18
100

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
421
100

Clinical Management of Adverse Events Associated with Lorlatinib.
Todd M Bauer, Enriqueta Felip, Benjamin J Solomon, Holger Thurm, Gerson Peltz, Marc D Chioda, Alice T Shaw. Oncologist 2019
44
100

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
T Mok, D R Camidge, S M Gadgeel, R Rosell, R Dziadziuszko, D-W Kim, M Pérol, S-H I Ou, J S Ahn, A T Shaw,[...]. Ann Oncol 2020
129
100


Genetic alterations defining NSCLC subtypes and their therapeutic implications.
Larissa A Pikor, Varune R Ramnarine, Stephen Lam, Wan L Lam. Lung Cancer 2013
174
100

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Qinhua Huang, Ted W Johnson, Simon Bailey, Alexei Brooun, Kevin D Bunker, Benjamin J Burke, Michael R Collins, Andrew S Cook, J Jean Cui, Kevin N Dack,[...]. J Med Chem 2014
65
100

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
100

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
363
100

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
452
100

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James C H Yang, Ji-Youn Han, Maximilian J Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario García Campelo, Dong-Wan Kim,[...]. J Clin Oncol 2020
115
100

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Andrew J Weickhardt, Dara L Aisner, Wilbur A Franklin, Marileila Varella-Garcia, Robert C Doebele, D Ross Camidge. Cancer 2013
55
100

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
614
100

CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.
Giulio Metro, Gianluigi Lunardi, Piero Floridi, Jennifer P Pascali, Luca Marcomigni, Rita Chiari, Vienna Ludovini, Lucio Crinò, Stefania Gori. J Thorac Oncol 2015
79
100

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
100

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti. Cancers (Basel) 2021
8
100

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose. Cancer Metastasis Rev 2015
61
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.